Amendments to the Specification

At page 3 of the published application, after paragraph [0029], please add the following section:

--**Brief Description of the Drawings**

Figure 1 depicts EGP-2 promoter (SEQ ID NO:5) analysis. The nucleotide sequence of the approx 4.2 kb BglII - SacII fragment was determined. The names of the generated deletions are at the right of the Figure: p39g47, p39E17.1, p39E152, p39E7 I, p39E[]l, p39EFl-1, p39E12-2 and p39E12-3. p39E was derived by cloning the approx 3.6 kb XmaIII restriction fragment. The end of each deletion is marked with "[". Putative transcription factor binding sites are marked Sp-1, Ap-1, Ets. The putative transcription start site is marked with a hooked arrow. Size markers depicted to the left of the Figure are relative to this putative transcription start site.

Figure 2 depicts EGP-2 promoter analysis. Deletion mutants of the EGP-2 promoter were fused to enhanced green fluorescent protein and transfected into non-epithelial cells, i.e., human fetal lung fibroblasts (FLF) cells and human umbilical vein endothelial cells (HUVEC), or epithelial cells SW948 (human colorectal carcinoma), or as a transfection and expression control into COS-7 cells (immortalized kidney epithelial cells derived from the African green monkey). Construct names (corresponding to Figure 1) are given above the line that represents the promoter. The numbers indicate the distance from the putative transcription start site that was given by Linnenbach et al (1993). In this Figure, the transcription start site is denoted as 1.--